Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity

Bagsværd, Denmark, 22 January 2014 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity.

Saxenda^®, the intended brand name of liraglutide 3 mg, is a once-daily glucagon-like peptide-1 (GLP-1) analogue, with 97% homology to naturally occurring human GLP-1, a hormone involved in appetite regulation.The CHMP positive opinion recommends that Saxenda^® will be indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of >= 30 kg/m² (obese), or >= 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

For further information

Media:
Mike Rulis	[phone]	[e-mail]
Ken Inchausti (US)	[phone]	[e-mail]
Investors:
Kasper Roseeuw Poulsen	[phone]	[e-mail]

Jannick Lindegaard Denholt

[phone]

[e-mail]

Melanie Raouzeos	[phone]	[e-mail]
Daniel Bohsen	[phone]	[e-mail]
Frank Daniel Mersebach (US)	[phone]	[e-mail]

Company announcement No 4 / 2015

Company announcement No 4 / 2015

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1889013